CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca and Summit Therapeutics.
BreakdownGenerated by LeadStory AI
- AstraZeneca is reportedly in talks with Summit Therapeutics to license a lung cancer drug for up to $15 billion. 10s
- The deal would involve licensing, not a full acquisition of Summit Therapeutics. 40s
- The experimental drug targets both PD1 and VEGF, aiming for improved lung cancer treatment. 1m 19s
- AstraZeneca has a history of successful oncology partnerships, such as with Daiichi Sankyo. 1m 7s